Cargando…

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report

Background: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner as per evidence-based clinical guidelines, is an important barrier limiting optimal care in the elderly. Therefore, overcoming therapeutic inertia is the core challenge when dealing with geria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dardano, Angela, Daniele, Giuseppe, Penno, Giuseppe, Miccoli, Roberto, Del Prato, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292593/ https://www.ncbi.nlm.nih.gov/pubmed/34307425 http://dx.doi.org/10.3389/fmed.2021.699477

Ejemplares similares

Optimal therapy of type 2 diabetes: a controversial challenge
por: Dardano, Angela, et al.
Publicado: (2014)

Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line
por: Sancho, Veronica, et al.
Publicado: (2017)

Insulin as an Early Treatment for Type 2 Diabetes: ORIGIN or end of an old question?
por: Del Prato, Stefano, et al.
Publicado: (2013)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
por: Dardano, Angela, et al.
Publicado: (2022)

Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge
por: Dardano, Angela, et al.
Publicado: (2020)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Treatment Inertia in Patients With Familial Hypercholesterolemia
por: Langer, Anatoly, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
por: Allevi, Massimiliano, et al.
Publicado: (2023)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
por: Pérez de Isla, Leopoldo, et al.
Publicado: (2023)

Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus
por: Lucchesi, Daniela, et al.
Publicado: (2018)

SIRT1 rs7896005 polymorphism affects major vascular outcomes, not all‐cause mortality, in Caucasians with type 2 diabetes: A 13‐year observational study
por: Dardano, Angela, et al.
Publicado: (2022)

Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study
por: Garofolo, Monia, et al.
Publicado: (2019)

Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
por: Garofolo, Monia, et al.
Publicado: (2021)

Nonadherence, Clinical Inertia, or Therapeutic Inertia?
por: Allen, J. Daniel, et al.
Publicado: (2009)

Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?
por: Dardano, Angela, et al.
Publicado: (2021)

Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study
por: Garofolo, Monia, et al.
Publicado: (2020)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
por: Nam, Chang-Wook, et al.
Publicado: (2019)

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
por: Gao, Fei, et al.
Publicado: (2022)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
por: Bruckert, Eric, et al.
Publicado: (2022)

Altered Visual Plasticity in Morbidly Obese Subjects
por: Lunghi, Claudia, et al.
Publicado: (2019)

Transforming the clunky organization: pragmatic leadership skills for breaking inertia
por: Bacharach, Samuel B
Publicado: (2018)

Effect of fasting on short‐term visual plasticity in adult humans
por: Animali, Silvia, et al.
Publicado: (2022)

Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men
por: Dell’Omo, Giulia, et al.
Publicado: (2014)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
por: Stroes, Erik, et al.
Publicado: (2016)

Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab
por: Tanaka, Hiroki, et al.
Publicado: (2020)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
por: Colhoun, Helen M., et al.
Publicado: (2020)

Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
por: Khunti, Sachin, et al.
Publicado: (2019)

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
por: Vallejo-Vaz, Antonio J, et al.
Publicado: (2020)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Self-Force and Inertia: Old Light on New Ideas
por: Lyle, Stephen
Publicado: (2010)

Obesity management: at the forefront against disease stigma and therapeutic inertia
por: Busetto, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_of2dq0hqinm8g32s744t6fp146